BLUWU = 1C + 1W


Prospectus 12/16/20

1 W + $11.50. $18 Call. $9.20 pipe protect

Term = 12 months + Two 3-month extensions at .10 each. Will allow redemption at each.

 Trust = $10.20. $58.7 million if the underwriters’ over-allotment option is exercised in full ($10.20 per unit). Placed into US trust account at J.P. Morgan Chase Bank with Continental Stock Transfer & Trust Company as trustee.

Focus Healthcare


Our founder, Joseph Hernandez, M.S., M.B.A, is an entrepreneurial leader with over 25 years of experience in the healthcare field. He has a background in company creation, early stage technology development, as well as private and public market financing. He brings leadership to the team, backed by a strong educational foundation in biology, medicine, molecular genetics, microbiology, epidemiology, marketing, and finance. Over the course of his career, he has founded or led eight entrepreneurial companies in cutting edge areas of healthcare and pharmaceuticals. After years of building his career at Merck & Co. (NYSE:MRK) from December 1998 to January 2001 and Digene from 2005 to 2009 (acquired by Qiagen (NYSE:QGEN)) from 2005 to 2009, Mr. Hernandez founded and became the President and CEO of Innovative Biosensors from 2004 to 2009. Later, Mr. Hernandez served as the Founder and Chairman of Microlin Bio Inc. from August 2013 to January 2017 and as Chairman of the Board of Ember Therapeutics (OTCMKTS:EMBT) from April 2014 to January 2019. He was also the Chairman of Sydys Corporation from May 2016 to January 2019. In 2018, Mr. Hernandez founded Blue Water Vaccines, an early stage biotechnology company focused on manufacturing a universal influenza vaccine in partnership with the University of Oxford in England. He has served as Chairman of Blue Water Vaccines, Inc. since 2019. Most recently, in January 2020, he founded and in May 2020 sold Noachis Terra, Inc. (acquired by Oragenics (NYSE:OGEN)) a company developing a vaccine for COVID-19. Mr. Hernandez brings experience in managing and interacting with diverse cultures, high level executives, and elected officials, to the team.

James Sapirstein, R.Ph., M.BA., has over 35 years of experience leading, founding, growing, and selling healthcare companies, specifically in the pharmaceutical space. His career began in sales at Eli Lilly, eventually rising to Director of International Marketing at Bristol Myers Squibb from July 1996 to June 2000, and later led the launch of Viread (tenofovir) at Gilead Sciences, Inc. (NASDAQ:GILD), where he served as Global Marketing Lead from June 2000 to June 2002. In November 2006 he became the founding CEO of Tobira Therapeutics (NASDAQ:TBRA), then a private company, and later acquired by Allergan (NYSE:AGN), where he served until January 2011. Since then, he has served as CEO of Alliqua Biomedical (NASDAQ:ALQA) from September 2012 to February 2014 and CEO of Contravir Pharmaceuticals (NASDAQ:CTRV) from March 2014 to October 2018, both publicly listed companies. He is currently the President and CEO of AzurRx BioPharma (NASDAQ:AZRX). He has been part of almost two dozen drug product launches and specifically either led or has been a key member of several HIV product launches into different new classes of therapeutics at the time. Additionally, Mr. Sapirstein holds board positions on Marizyme (OTCMKTS:MRZM) (Executive Chairman) Enochian Biosciences (NASDAQ:ENOB), and Leading Biosciences. He served as Chairman of the Board for BioNJ, an association of biopharma industries in New Jersey from February 2017 through February 2019. He is also a Board Director for BIO, the leading Biopharma Industries Organization promoting public policy and networking in the healthcare space, where he sits on both the Health Section and Emerging Companies Section Governing Boards. Mr. Sapirstein brings a unique combination of healthcare and business experience to the team from his BS in Pharmacy and MBA, along with an expansive network from decades in the healthcare industry.

Kimberly Murphy has more than 25 years of experience at leading pharmaceutical companies including Novartis (NYSE:NVS) and Merck & Co (NYSE:MRK). In her distinguished career at Merck, she rose through various public affairs and business roles to leadership positions as Region Marketer for U.S. Commercial Operations, U.S. Marketing Leader for Adult Vaccines and Director of the HPV/Gardasil Franchise. Most recently, Ms. Murphy served as VP of the Influenza Franchise and Global Vaccine Commercialization Leader at GlaxoSmithKline (NYSE:GSK). With full P&L for the Influenza product line, one of the fastest growing franchises in the company globally, she delivered $1 billion in sales, a 70% increase in protected patients and significantly improved profitability. She achieved this by scaling and transforming the organization — across multiple R&D and manufacturing sites — to a continuous improvement culture with a customer experience mindset and a competitive eCommerce platform. Ms. Murphy has Board and Advisory experience that includes serving on the Boards of Oragenics, Inc. (NYSE: OGEN), and Blue Water Vaccines, Inc., as well as the GSK Representative to the Biotechnology Industry Organization’s Biodefense Advisory Council, and on the St. Joseph’s University Pharmaceutical & Healthcare Marketing MBA Program’s Advisory Board.

Michael Lerner has over 30 years of experience providing strategic judgment and practical advice regarding diverse matters for pharmaceutical, life sciences, and health care companies. Mr. Lerner has a background in product acquisitions and divestitures, technology licensing, sales and marketing practices, mergers and acquisitions, intellectual property, corporate compliance, employment law, and regulatory matters. Prior to joining Lowenstein Sandler as Chair of the Life Sciences Group, He was Senior Vice President and General Counsel of EKR Therapeutics, a specialty pharmaceutical company focusing on acute care hospital products. That position followed six years as Vice President and General Counsel at Reliant Pharmaceuticals Inc., which Michael helped grow into one of the nation’s largest privately held pharmaceutical companies before it was acquired by GlaxoSmithKline in 2007. As part of Reliant’s senior management team, he was named lead inside lawyer on product acquisitions and dispositions. Mr. Lerner brings valuable expertise in legal considerations of the life science industry, as well as a documented track record of public speaking and professional presentations to the team.

Yvonne McBurney has over 30 years of business leadership experience in the healthcare field. Ms. McBurney has successfully developed and executed strategic business plans to drive consistent above-plan performance by optimizing group synergies, building high-performing diverse teams, and driving cultural change. During her career, she has acquired a reputation for working with the highest level of integrity. Since March 2020, Ms. McBurney has been VP of Operations at Alivia Specialty Pharmacy. That position followed ten years at GlaxoSmithKline (NYSE:GSK), beginning in January 2010 where she was ultimately appointed to lead the US Commercial and Medical Affairs integration of TESARO, an oncology focused biopharmaceutical company. She also held the Puerto Rico General Manager role for six years and delivered significant revenue and margin growth. Prior to GSK, Ms. McBurney was the General Manager of Wyeth Puerto Rico from April 2006 to November 2009.

Jon Garfield has over 20 years of financial leadership experience, including with healthcare companies. Mr. Garfield regularly provides consulting services to private equity funds and privately held companies. He has served as a consultant of Bay State Physical Therapy from June 2018 to February 2019 and also as a director beginning in February 2019. From 2016 to 2017, Mr. Garfield was the CFO of Pyramid Healthcare, also a private equity based healthcare company. Prior to Pyramid Healthcare, Mr. Garfield joined Monte Nido as CFO in 2012 until 2016. Before Monte Nido, he served as CFO of Clearant, Inc., a publicly-traded medical device company, and Network IP and Simplified Development, where he oversaw the finance and treasury functions, implemented systems upgrades, and pursued a number of growth initiatives. Mr. Garfield was previously a Co-Founder and Vice President of Acquisitions for Coach USA, a consolidator of ground transportation entities throughout North America, and was heavily involved in over 50 acquisitions and the eventual IPO of the company. Earlier in his career, he held positions with PricewaterhouseCoopers and Arthur Andersen.

***GREENWICH, Conn., Dec. 17, 2020 /PRNewswire/ -- Blue Water Acquisition Corporation (NASDAQ: BLUWU) (the "Company"), a special purpose acquisition company, announced today that it closed its initial public offering of 5,750,000 units, which includes 750,000 units issued pursuant to the full exercise by the underwriter of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $57,500,000. Each unit consisted of one share of the Company's Class A common stock and one redeemable warrant to purchase one share of Class A common stock at an initial exercise price of $11.50 per share.

The units are listed on The Nasdaq Capital Market ("Nasdaq") and began trading under the ticker symbol "BLUWU" on December 15, 2020. Once the securities comprising the units begin separate trading, the common stock and warrants are expected to be listed on Nasdaq under the symbols "BLUW" and "BLUWW," respectively. Blue Water Acquisition Corporation was founded by Joseph Hernandez, a life sciences entrepreneur.

Maxim Group LLC acted as sole book running manager in the offering.